Syncom Formulations Share Price Today

Syncom Formulations declares ₹0.10 per share final dividend for FY26

Final dividend of ₹0.10 per equity share approved for FY26. Record date fixed at September 23, 2026 for dividend entitlement. Total payout obligation estimated at approximately ₹9.4 crore. Shareholders ratified appointment of Rahul Vijay Bankda as MD. Institutional investors opposed CFO remuneration increase by 99.63%.

Syncom Formulations promoters waive ₹4.75 crore dividend for FY26

Promoters waived dividend on 47.53 crore shares held. Total dividend waiver amounts to ₹4.75 crore. Net dividend payable reduces to ₹4.64 crore. Waiver is voluntary and unconditional per SEBI norms.

Syncom Formulations sets record date for ₹0.10 final dividend

Syncom Formulations fixes September 23, 2026, as the record date for its final dividend. The proposed payout is ₹0.10 per equity share of face value ₹1 for FY26. Shareholder approval at the AGM on September 30, 2026, is required for the payout. Dividend waivers must be submitted by September 26, 2026.

Syncom Formulations AGM to approve Rahul Bankda as MD, Rinki Bankda as WTD

Syncom Formulations schedules 38th AGM for September 30, 2026. Rahul Bankda appointed MD; Rinki Bankda appointed WTD. Final dividend of ₹0.10 per share proposed for FY26. CFO Ankur Bankda's salary increased to ₹3.5 lakh per month.

Syncom Formulations files FY26 BRSR report with sustainability metrics

Syncom Formulations filed its BRSR report for FY26 on September 7, 2026. Exports drive **82.94%** of total standalone sales turnover of ₹48,657.28 lakh. Total energy consumption increased to **65,68,586.4** units in FY26. Permanent employee turnover rose to **28%** from **25%** in the prior year. Pharmaceutical manufacturing contributes **92.62%** of entity turnover.

Syncom Formulations net profit rises 57.7% in Q1FY27 on margin expansion

Syncom Formulations (India) Limited delivered strong Q1FY27 results with consolidated net profit rising 57.7% to ₹2484.68 lakh. Revenue grew 7.3% to ₹12552.64 lakh, but the primary driver was margin expansion, with EBITDA margins jumping to 20.87%. The company demonstrated effective cost control, reducing standalone expenses despite higher income.